There are many dimensions and possible pitfalls here. Uncertain mechanism of action, objectionable comparison arms, the high-bar goal of resistant depression that might lead to failure. This seems like a mix situation of a new type of antidepressant (like agomelatin which was of modest effect) and cannabis (which is traded as painkiller but people use it for recreation).
No comments yet.